AAAAAA

   
Results: 1-9 |
Results: 9
Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease
Authors: Golde, TE Eckman, CB
Citation: Te. Golde et Cb. Eckman, Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease, DRUG DISC T, 6(20), 2001, pp. 1049-1055
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation
Authors: Nilsberth, C Westlind-Danielsson, A Eckman, CB Condron, MM Axelman, K Forsell, C Stenh, C Luthman, J Teplow, DB Younkin, SG Naslund, J Lannfelt, L
Citation: C. Nilsberth et al., The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation, NAT NEUROSC, 4(9), 2001, pp. 887-893
Reduction of A beta accumulation in the Tg2576 animal model of Alzheimer'sdisease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin
Authors: Haugabook, SJ Le, T Yager, D Zenk, B Healy, BM Eckman, EA Prada, C Younkin, L Murphy, P Pinnix, I Onstead, L Sambamurti, K Golde, TE Dickson, D Younkin, SG Eckman, CB
Citation: Sj. Haugabook et al., Reduction of A beta accumulation in the Tg2576 animal model of Alzheimer'sdisease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin, FASEB J, 15(1), 2001, pp. 16-18
High throughput screens for the identification of compounds that alter theaccumulation of the Alzheimer's amyloid beta peptide (A beta)
Authors: Haugabook, SJ Yager, DM Eckman, EA Golde, TE Younkin, SG Eckman, CB
Citation: Sj. Haugabook et al., High throughput screens for the identification of compounds that alter theaccumulation of the Alzheimer's amyloid beta peptide (A beta), J NEUROSC M, 108(2), 2001, pp. 171-179
Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme
Authors: Eckman, EA Reed, DK Eckman, CB
Citation: Ea. Eckman et al., Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme, J BIOL CHEM, 276(27), 2001, pp. 24540-24548
Biochemical detection of A beta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease
Authors: Golde, TE Eckman, CB Younkin, SG
Citation: Te. Golde et al., Biochemical detection of A beta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease, BBA-MOL BAS, 1502(1), 2000, pp. 172-187
Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain
Authors: Harigaya, Y Saido, TC Eckman, CB Prada, CM Shoji, M Younkin, SG
Citation: Y. Harigaya et al., Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain, BIOC BIOP R, 276(2), 2000, pp. 422-427
Glycosylphosphatidylinositol-anchored proteins play an important role in the biogenesis of the Alzheimer's amyloid beta-protein
Authors: Sambamurti, K Sevlever, D Koothan, T Refolo, LM Pinnix, I Gandhi, S Onstead, L Younkin, L Prada, CM Yager, D Ohyagi, Y Eckman, CB Rosenberry, TL Younkin, SG
Citation: K. Sambamurti et al., Glycosylphosphatidylinositol-anchored proteins play an important role in the biogenesis of the Alzheimer's amyloid beta-protein, J BIOL CHEM, 274(38), 1999, pp. 26810-26814
gamma-Secretase, evidence for multiple proteolytic activities and influence of membrane positioning of substrate on generation of amyloid beta peptides of varying length
Authors: Murphy, MP Hickman, LJ Eckman, CB Uljon, SN Wang, R Golde, TE
Citation: Mp. Murphy et al., gamma-Secretase, evidence for multiple proteolytic activities and influence of membrane positioning of substrate on generation of amyloid beta peptides of varying length, J BIOL CHEM, 274(17), 1999, pp. 11914-11923
Risultati: 1-9 |